Status:
COMPLETED
D-serine Supplementation for Depression
Lead Sponsor:
André Schmidt
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The glutamate system is emerging as target for the development of novel antidepressant medication, in particular compounds modulating the NMDA receptor. While the NMDA receptor antagonist ketamine is ...
Eligibility Criteria
Inclusion
- Age 18-60
- Inpatients with a diagnosis of MDD with a current moderate-to-severe episode (HAM-D score \> 16) (7)
- Treatment as usual (TAU) for depression. TAU for depression may include no treatment at all or standard pharmacotherapy (antidepressants and antipsychotics such as aripiprazole, risperidone or quetiapine) and / or psychotherapy.
- Able to read and understand study procedures and participant's information
Exclusion
- Other primary psychiatric diagnoses than MDD such as substance use and psychotic disorders
- Serious suicide attempts
- Contradiction for MRI (no pacemaker, MRI incompatible metal implants or splinters in the body, past heart/head surgery, past stroke/brain injury, claustrophobia)
- Pregnant or lactating women (pregnancy test)
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2024
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04721249
Start Date
July 1 2021
End Date
January 30 2024
Last Update
May 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Basel, Department of Psychiatry (UPK)
Basel, Canton of Basel-City, Switzerland, 4002